August 11, 2022

The biopharmaceutical industry saw a decline in deal activity in 2021, possibly due to the risk of delayed closure, renegotiation or termination owing to COVID-19 uncertainty.

Growth was driven mainly by Oncology & Neurology partnerships and Mergers & Acquisitions, with an increase in the number of partnerships for products in the early stage of development.

Read the latest Syneos Health Consulting BioPharma Business Development Newsletter to learn more about growth differentiated by location, therapeutic area and development phase—with a spotlight on Cell and Gene Therapy. 

Download the newsletter below

Scroll to Page Bottom Form